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Functional spliceosomal A complexes can be assembled
in vitro in the absence of a penta-snRNP
NASTARAN BEHZADNIA, KLAUS HARTMUTH, CINDY L. WILL, and REINHARD LU¨HRMANN
Department of Cellular Biochemistry, Max Planck Institute for Biophysical Chemistry, D-37077 Go¨ttingen, Germany
ABSTRACT
Two different models currently exist for the assembly pathway of the spliceosome, namely, the traditional model, in which
spliceosomal snRNPs associate in a stepwise, ordered manner with the pre-mRNA, and the holospliceosome model, in which all
spliceosomal snRNPs preassemble into a penta-snRNP complex. Here we have tested whether the spliceosomal A complex,
which contains solely U1 and U2 snRNPs bound to pre-mRNA, is a functional, bona fide assembly intermediate. Significantly, A
complexes affinity-purified from nuclear extract depleted of U4/U6 snRNPs (and thus unable to form a penta-snRNP) supported
pre-mRNA splicing in nuclear extract depleted of U2 snRNPs, whereas naked pre-mRNA did not. Mixing experiments with
purified A complexes and naked pre-mRNA additionally confirmed that under these conditions, A complexes do not form de
novo. Thus, our studies demonstrate that holospliceosome formation is not a prerequisite for generating catalytically active
spliceosomes and that, at least in vitro, the U1 and U2 snRNPs can functionally associate with the pre-mRNA, prior to and
independent of the tri-snRNP. The ability to isolate functional spliceosomal A complexes paves the way to study in detail
subsequent spliceosome assembly steps using purified components.
Keywords: spliceosome; pre-mRNA splicing; A complexes
INTRODUCTION
Many nuclear processes such as transcription initiation by
RNA polymerases I and II, DNA repair by nuclear excision,
and pre-mRNA splicing require the combined action of
numerous factors that are components of complex molec-
ular machines. In many cases, it is not entirely clear how
these ‘‘machines’’ assemble onto their substrates. Different
models ranging from (1) the stepwise assembly of in-
dividual components or subcomplexes of these machines
to (2) the interaction of preassembled holocomplexes have
been discussed (for review, see Lemon and Tjian 2000;
Brow 2002; Nilsen 2002). Experimentally, it can often prove
difficult to distinguish between these two possibilities,
perhaps as best exemplified by the numerous conflicting
reports regarding the assembly pathway of those molecular
machines responsible for transcription initiation and DNA
repair. In vivo kinetic experiments have only recently
provided solid evidence that transcription and DNA repair
proteins diffuse in relatively small complexes and assemble
in a sequential order at their sites of action (Dundr et al.
2002; Hoogstraten et al. 2002), rather than existing in
preassembled holocomplexes as previously proposed
(Svejstrup et al. 1995; Maldonado et al. 1996; Hannan
et al. 1999).
Different models also currently exist for the assembly
pathway of the spliceosome, the large ribonucleoprotein
complex that catalyzes intron removal from pre-mRNAs.
The spliceosome is composed of the U1, U2, U4/U6, and
U5 snRNPs, and a large number of splicing factors (Burge
et al. 1999; Will and Lu¨hrmann 2006). Spliceosome
assembly was initially characterized by an extensive array
of in vitro studies using human and yeast cell extracts.
Several biochemical approaches, including native gel elec-
trophoresis (Konarska and Sharp 1986; Cheng and Abelson
1987), gradient centrifugation (Brody and Abelson 1985;
Frendewey and Keller 1985; Grabowski et al. 1985), and
affinity chromatography (Bindereif and Green 1987),
revealed a sequential appearance of spliceosomal complexes
that differ in their snRNP composition. These findings
resulted in the development of a model in which spliceo-
some assembly occurs by the stepwise interaction of
spliceosomal components with the pre-mRNA (for review,
see Will and Lu¨hrmann 2006). According to this model,
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spliceosome assembly in mammals is initiated by the ATP-
independent interaction of the U1 snRNP with the 59 splice
site, forming the so-called E complex. The U2 snRNP is
loosely associated at this stage (Das et al. 2000), and
subsequently, in an ATP-dependent manner, it stably
interacts with the branch point sequence (BPS) of the
pre-mRNA, forming the A complex. At this stage the 59 and
39 splice sites are functionally paired (Lim and Hertel
2004). In the next step, the pre-formed 25S U4/U6dU5 tri-
snRNP is recruited to the A complex to form the precata-
lytic B complex. Dramatic structural rearrangements result-
ing in the destabilization of the U1 and U4 snRNPs
generate the catalytically activated spliceosome (B* com-
plex). Subsequently, the first catalytic step of splicing occurs,
and the C complex is generated. After the second step of
splicing, the mRNA is released and the post-spliceosomal
complex—containing the excised intron and the U2, U5,
and U6 snRNPs—disassembles, and the snRNPs are recycled
to take part in new rounds of splicing.
A similar stepwise assembly pathway was also proposed
for the Saccharomyces cerevisiae spliceosome, as equivalent
intermediates are detected in vitro (for review, see Burge
et al. 1999). Two reports using chromatin immunoprecip-
itation (ChIP) to investigate spliceosome assembly in yeast
in vivo also support the stepwise assembly model. That is,
data from these assays indicate that the U1 and U2 snRNPs,
the key components of the A complex, bind cotranscrip-
tionally to the nascent pre-mRNA but prior to the U4/
U6dU5 tri-snRNP (Go¨rnemann et al. 2005; Lacadie and
Rosbash 2005). By combining ChIP assays with in vivo
depletion of different spliceosomal snRNPs, additional
evidence has recently been provided that the yeast snRNPs
are recruited stepwise to the pre-mRNA in vivo (Tardiff
and Rosbash 2006). However, in higher eukaryotes, the
mechanism of spliceosome assembly in vivo is not known.
Several studies carried out in cell extracts identified
interactions that are difficult to reconcile with the temporal
order of events depicted in the stepwise assembly model.
For example, cross-linking studies in HeLa cell and yeast
cell extract demonstrated an early interaction between the
U4/U6dU5 tri-snRNP and the 59 splice site that occurs prior
to stable binding of the U2 snRNP to the pre-mRNA
branch point (Maroney et al. 2000; Johnson and Abelson
2001). Similarly, it was shown that when the 59-end of U1 is
sequestered, the U4/U6dU5 tri-snRNP can bind an oligo-
ribonucleotide, mimicking the 59 splice site; as the BPS
is lacking, this interaction can occur in the absence of
a U2–BPS interaction (Konforti et al. 1993; Konforti and
Konarska 1994, 1995).
Furthermore, several observations suggest that the U1
and/or U2 snRNPs interact with the U4/U6dU5 tri-snRNP
prior to engaging the pre-mRNA. For example, psoralen
cross-linking of RNAs in nuclear extract in the absence of
pre-mRNA revealed an endogenous U2–U4–U6 cross-linkable
complex (Hausner et al. 1990; Wassarman and Steitz 1992).
Furthermore, U2, U4, U5, and U6 snRNPs associate ef-
ficiently in the absence of pre-mRNA, either when HeLa
cell nuclear extract is incubated at 200–300 mM NH4Cl
(Konarska and Sharp 1988) or under splicing conditions
when a short oligonucleotide mimicking the 59 splice site is
added to the extract (Hall and Konarska 1992). More
recent studies revealed that a large 200S complex contain-
ing the U1, U2, U4, U5, and U6 snRNPs can assemble onto
a short RNA containing a 59 splice site in HeLa cell nuclear
extract, consistent with the existence of a human U1/U2/
U4/U5/U6 penta-snRNP (Malca et al. 2003). In S. cerevisiae,
a pre-formed U1/U2/U4/U5/U6 penta-snRNP could be
isolated under low salt conditions from yeast cell extract.
Significantly, this complex was shown to function as an
intact entity in in vitro splicing assays when supplemented
with micrococcal nuclease-treated extract (Stevens et al.
2002).
Based on the latter studies, an alternative model for
spliceosome assembly was proposed. In this model, the
spliceosome preassembles in the absence of the pre-mRNA,
and all of the snRNPs (as part of this ‘‘holospliceosome’’)
engage the pre-mRNA concomitantly. In subsequent
remodeling steps, initially weak contacts between the
spliceosome and the pre-mRNA are progressively stabilized
through dynamic RNA/RNA rearrangements, and a catalyt-
ically active spliceosome is ultimately formed. Proponents
of this model suggest that due to the relatively harsh
conditions typically used to investigate spliceosome assem-
bly in vitro, the various assembly intermediates that are
observed (i.e., E, A, and B) simply reflect the stepwise
stabilization of snRNP–pre-mRNA interactions, rather than
a stepwise recruitment of snRNPs. Thus, according to the
holospliceosome model, spliceosomal complexes such as
the A complex do not represent bona fide functional as-
sembly intermediates, but rather arise by dissociation of
the holospliceosome.
Here, we have investigated whether the human A
complex represents a genuine, spliceosome assembly in-
termediate. For this purpose, spliceosomal A complexes
were isolated by a two-step purification method, involving
tobramycin affinity selection followed by immunoaffinity
purification, and subsequently tested for splicing activity in
nuclear extract depleted of U2 snRNPs. Significantly, A
complexes isolated from either intact HeLa cell nuclear
extract or from extract that was depleted of U4/U6 snRNPs
(and thus unable to form a penta-snRNP) supported
splicing in U2-depleted extract, whereas naked tagged
pre-mRNA did not. Furthermore, in the presence of an
equimolar amount of purified A complexes, splicing of
naked untagged pre-mRNA was not observed, demonstrat-
ing that A complexes do not dissociate and form de novo in
the U2-depleted extract. Taken together, our data provide
evidence that in the human system, at least in vitro,
spliceosome assembly does not require the formation of
a holospliceosome. Rather, functional spliceosomes can
In vitro assembly of functional A complexes
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assemble on the pre-mRNA from the U1 and U2 snRNPs
and the (U4/U6dU5) tri-snRNP in a stepwise and tempo-
rally ordered manner. A complexes purified in this way can
potentially be used to reconstitute catalytically active
spliceosomes from purified spliceosomal components, and
thus enable a detailed dissection of the stepwise assembly
pathway of the spliceosome.
RESULTS
Affinity purification of the human spliceosomal
A complex
To investigate whether the spliceosomal A complex is
a bona fide assembly intermediate, we first affinity-purified
this complex from HeLa cell nuclear extract under native
conditions and tested whether it is active in splicing. For
this purpose, we performed tobramycin affinity selection,
as previously described to isolate human A complexes
(Hartmuth et al. 2002), but included an additional immu-
noaffinity selection step to ensure that highly pure com-
plexes were obtained. Briefly, MINX pre-mRNA tagged
with a tobramycin RNA aptamer was first immobilized on
a tobramycin-derivatized Sepharose matrix and incubated
for 45 min under splicing conditions with HeLa cell nuclear
extract. Assembled spliceosomal complexes were eluted by
competition with tobramycin, and the eluate was subjected
to immunoaffinity selection using anti-peptide antibodies
against the U2-associated SF3a66 protein. After eluting
with antigenic peptide, spliceosomal complexes (i.e., a mix-
ture of A and B) were further separated on a 10%–30%
glycerol gradient, and the distribution of RNA across the
gradient was analyzed by denaturing PAGE. As shown in
Figure 1, complexes containing equimolar amounts of the
U1 and U2 snRNAs and the pre-mRNA (i.e., A complexes)
peaked in fractions 10 and 11 and were well separated from
complexes containing all of the spliceosomal snRNAs (i.e.,
B complexes), which peaked in fraction 16 (Fig. 1). Mass
spectrometry analyses of A complexes purified in this way
revealed that their protein composition is very similar to
that of the previously reported human A complex (Hartmuth
et al. 2002; data not shown; N. Behzadnia, K. Hartmuth,
H. Urlaub, and R. Lu¨hrmann, in prep.). In the following
experiments, A complexes from gradient fraction 10 were
used.
Affinity-purified A complexes are functional
To test whether our purified A complexes are functional, as
opposed to being ‘‘dead-end complexes,’’ we performed
splicing assays in vitro with HeLa cell nuclear extract that
was depleted of the 12S form of the U2 snRNP and thus
cannot form a holospliceosome. U2 snRNPs were depleted
by incubating the extract with a biotinylated 29-OMe RNA
oligonucleotide complementary to the 59-end of the U2
snRNA, followed by streptavidin agarose affinity selection
(Barabino et al. 1990; Se´gault et al. 1995). Analysis of the
snRNA composition of the mock-depleted versus U2-
depleted extract confirmed that the U2 snRNP was quan-
titatively removed (Fig. 2A, cf. lanes 1 and 2). U2-depleted
(DU2) extract did not support the splicing of tobramycin
aptamer-tagged MINX or untagged MINX pre-mRNA, or
an equimolar mixture of both substrates (Fig. 2B, lanes
1,3,5). In contrast, both pre-mRNAs were efficiently spliced
in the mock-depleted extract (Fig. 2B, lanes 7,9,11).
Furthermore, preincubation of the DU2 extract with
purified 12S U2 snRNP restored splicing of both substrates
to the level observed with the mock-depleted extract (Fig.
2B, cf. lanes 2,4,6 and 7,9,11, respectively), whereas splicing
activity of the mock-depleted extract was unaffected by 12S
U2 snRNP addition (Fig. 2B, lanes 8,10,12). These results
confirm that the splicing defect is due specifically to the
depletion of the 12S U2 snRNP. Thus, the DU2 extract
should contain all of the factors necessary to chase a pre-
assembled A complex into a catalytically active spliceosome.
In contrast to naked, untagged MINX pre-mRNA,
purified A complexes could be chased in DU2 extract into
mature spliceosomes that catalyzed both steps of splicing
(Fig. 2C, lane 2). To rule out the possibility that U2 snRNPs
dissociate from the exogenously added, purified complexes
and that A complexes subsequently assemble de novo from
components of the DU2 extract, we performed a mixing
experiment. Equimolar amounts of untagged MINX pre-
mRNA and purified A complex (containing tagged MINX
pre-mRNA) were incubated under splicing conditions in
the DU2 extract. Significantly, only spliced mRNA and
lariat intermediate from the tagged pre-mRNA, but not
FIGURE 1. Characterization of spliceosomal A complexes purified
via tobramycin affinity selection followed by immunoaffinity selection
and gradient centrifugation. Complexes were separated on a 10%–
30% glycerol gradient. RNA was recovered from each gradient
fraction (as indicated above), analyzed by denaturing PAGE, and
visualized by silver staining (upper panel) or by autoradiography
(lower panel). The identity of the various RNAs is indicated on
the right. Contaminating high molecular weight RNAs are indicated
by an asterisk. ‘‘PRE’’ indicates the pre-mRNA. 30S and 50S cor-
respond to migration positions of E. coli ribosomal subunits in par-
allel gradients.
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from the untagged pre-mRNA, were observed (Fig. 2C, lane
3), even after extended incubation times (i.e., 180 min).
Note that the cleaved exon 1 and excised intron lariat
generated from both substrates are identical. Therefore, we
conclude that A complexes do not form de novo under
these conditions and that the spliceosomal A complex
purified from HeLa cell nuclear extract is functional.
Spliceosomal A complexes purified from
U4/U6-depleted nuclear extract are functional
As A complexes were isolated from nuclear extract in which
a penta-snRNP could potentially be formed, it is possible
that the complexes that we isolated were generated via
dissociation of holospliceosomes during the purification
procedure. To exclude such a possibility, we tested whether
functional spliceosomal A complexes are also formed in
a nuclear extract devoid of a penta-snRNP. To this end we
first codepleted U4 and U6 snRNPs from nuclear extract by
affinity selection with a biotinylated 29-OMe RNA oligo-
nucleotide complementary to the 39-end of the U6 snRNA
(Blencowe et al. 1989). Analysis of the RNA composition of
the depleted versus mock-depleted extract indicated that
U4/U6 snRNPs were quantitatively removed (Fig. 3A, lane
2). Thus, the DU4/U6 extract cannot support the formation
of the U4/U6dU5 tri-snRNP or penta-snRNP. Consistent
with the observation that even in the absence of pre-mRNA
the U2 snRNP associates with U4/U6 snRNPs in HeLa cell
nuclear extract (Wassarman and Steitz 1992), a portion of
the U2 snRNP was codepleted together with the U4/U6
snRNP. As expected, the DU4/U6 extract did not support
splicing (data not shown). However, consistent with pre-
vious reports (Barabino et al. 1990; Wolff and Bindereif
1992), DU4/U6 extract supported the efficient assembly of
the spliceosomal A complex, but not the B complex, as
assayed by native gel electrophoresis (Fig. 3B) and glycerol
gradient centrifugation (Fig. 3C).
We next purified the A complex from DU4/U6 extract
using the double affinity selection procedure described
above. After eluting with antigenic peptide, spliceosomal
complexes were further separated on a 10%–30% glycerol
gradient, and the distribution of RNA across the gradient
was analyzed by denaturing PAGE. As shown in Figure 4A,
complexes containing equimolar amounts of the U1 and
U2 snRNAs and the pre-mRNA peaked in fractions 9–11,
similar to A complexes isolated from intact HeLa cell
nuclear extract (Fig. 1).
Significantly, A complexes purified from extract devoid
of a holospliceosome could be chased in DU2 extract into
mature spliceosomes that catalyzed both steps of splicing
(Fig. 4A, lane 2). To again rule out de novo assembly of A
complexes in the DU2 extract, splicing was performed with
a mixture of the purified A complex and an equimolar
amount of untagged MINX pre-mRNA. Significantly, only
spliced mRNA and lariat intermediate from the tagged pre-
mRNA present in the purified A complex, but not from the
untagged pre-mRNA, were observed (Fig. 4B, lane 3), even
after extended incubation times. We note that the amount
of mRNA in lane 3 is less than that observed in lane 2
(quantification revealed a decrease of z37%). However,
significant change in the level of spliced intron lariat was
not observed upon addition of the untagged MINX pre-
mRNA, indicating that the overall splicing efficiency of the
tagged substrate did not decrease but, rather, that the
tagged-mRNA was selectively degraded. To demonstrate
that the untagged MINX pre-mRNA can be spliced under
these conditions, we complemented the DU2 extract with
purified 12S U2 snRNPs. Indeed, in the presence of
exogenously added U2, both the tagged pre-mRNA (pres-
ent in the purified A complexes), as well as the naked
untagged MINX pre-mRNA, were spliced (Fig. 4B, lane 4).
We therefore conclude that the A complex formed in the
FIGURE 2. Double affinity-purified A complexes are functional. (A)
RNA composition of U2 snRNP-depleted (lane 2) and mock-depleted
(lane 1) extracts. RNA was separated by denaturing PAGE and
detected by staining with ethidium bromide. The identity of the
various RNAs is indicated on the left; 5.8S rRNA is indicated by an
asterisk. (B) In vitro splicing of mock- vs. U2-depleted extract. An
equimolar mixture of 32P-labeled tobramycin aptamer-tagged MINX
pre-mRNA (MINX-To) and MINX pre-mRNA (lanes 1,2,7,8), MINX
pre-mRNA alone (lanes 3,4,9,10), or MINX-To pre-mRNA alone
(lanes 5,6,11,12) were incubated under splicing conditions for 3 h at
30°C in the presence of U2-depleted nuclear extract (lanes 1,3,5), U2-
depleted extract complemented with purified 12S U2 snRNP (lanes
2,4,6), mock-depleted extract (lanes 7,9,11), or mock-depleted extract
plus purified 12S U2 snRNP (lanes 8,10,12). RNA was recovered and
analyzed by denaturing PAGE and visualized by autoradiography. The
positions of the pre-mRNAs, the splicing intermediates, and the
products are indicated on the right. (C) Splicing activity of purified A
complexes. Purified spliceosomal A complexes from gradient fraction
10 (lanes 1,2) or an equimolar mixture of the purified A complex and
naked, untagged MINX pre-mRNA (lane 3) were incubated in the
presence of U2-depleted extract for 3 h at 0°C (lane 1) or at 30°C
(lanes 2,3). RNA was analyzed as in B. Similar results were obtained
with A complexes from gradient fractions 9, 11, and 12.
In vitro assembly of functional A complexes
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absence of an intact U4/U6dU5 tri-snRNP and penta-
snRNP is functional and not a dead-end product. Taken
together, these studies demonstrate that functional human
A complexes can assemble in a stepwise manner.
DISCUSSION
Much discussion has recently been focused on the assembly
pathway of the highly complex, multicomponent splicing
machinery. The identification and characterization of
a splicing-active penta-snRNP complex in budding yeast
(Stevens et al. 2002) challenged the traditional model of
spliceosome assembly, in which spliceosomal snRNPs
associate in a stepwise, temporally ordered manner. Recent
observations suggest that a penta-snRNP may also form in
human cell extracts in the absence of the pre-mRNA (Malca
et al. 2003). However, definitive proof that such a complex
indeed exists and, additionally, functions in splicing is still
lacking. To reconcile the apparent existence of a holospli-
ceosome with the fact that numerous spliceosome assembly
intermediates are detected using in vitro approaches, such
as native gel electrophoresis or gradient centrifugation, it
was proposed that the observed assembly intermediates
could reflect different states of the spliceosome in which
certain components are merely more stably associated with
the pre-mRNA. Only the most stable interactions would
withstand the stringent conditions used to study the
spliceosome, giving rise to the appearance of the various
spliceosomal complexes. Thus, according to this view, A
complexes detected by various biochemical methods would
represent a breakdown product of the holospliceosome and
not a bona fide assembly intermediate.
Data presented here clearly demon-
strate that this is not the case. That is,
we provide evidence that human splice-
osomal A complexes assembled in vitro
are functional, even under conditions
excluding the formation of a holo-
spliceosome. Thus, our studies clearly
demonstrate that the formationof a holo-
spliceosome is not a prerequisite for
generating catalytically active spliceo-
somes. Rather, our data provide evi-
dence that, at least in vitro, the U1 and
U2 snRNPs can associate with the pre-
mRNA, prior to and independent of the
tri-snRNP, and form functional prespli-
ceosomal complexes. Previous studies
with partially purified human E and A
complexes also suggested that these
early spliceosomal complexes are func-
tional assembly intermediates (Michaud
and Reed 1991). More recent studies
performed with MS2-affinity-purified E
and A complexes also indicated that
both of these complexes are functional; that is, E and A
complexes purified from intact HeLa nuclear extract could
be chased into catalytically active spliceosomes in nuclear
extract depleted of SF3a (Das et al. 2000). In vivo studies
using chromatin immunoprecipitation (ChIP) or ChIP
combined with in vivo snRNP depletions also support
a stepwise assembly of the spliceosome in budding yeast
(Go¨rnemann et al. 2005; Lacadie and Rosbash 2005; Tardiff
and Rosbash 2006). Data from our laboratory and that of
others, as well as data supporting the holospliceosome
model, do not rule out that both pathways can exist both
in vivo and in vitro; i.e., under some conditions, active
spliceosomes might be formed via the holospliceosome
pathway, and under others, stepwise recruitment of snRNPs
may occur.
HeLa cells are known to contain a several-fold excess of
U1 and U2 snRNPs over components of the tri-snRNP.
Thus, a large portion of these snRNPs will clearly not be
present as part of a penta-snRNP and will be capable of
interacting with the pre-mRNA as such. Likewise, U1
snRNPs are present in excess over the other spliceosomal
snRNPs in yeast cells. Although our data demonstrate that
U1 and U2 can functionally associate with the pre-mRNA
prior to the tri-snRNP, they do not demonstrate that there
is a fixed, temporal order of snRNP association. Indeed,
several studies suggest that there is an early interaction
between the U4/U6dU5 tri-snRNP and the 59 splice site that
does not require prior stable binding of the U2 snRNP to
the BPS (Maroney et al. 2000; Johnson and Abelson 2001).
Our data indicate, however, that an early tri-snRNP/59-ss
interaction is not required for the formation of an active
spliceosome.
FIGURE 3. U4/U6-depleted nuclear extract supports the formation of only spliceosomal A
complexes. (A) RNA composition of U4/U6-depleted (lane 2) and mock-depleted (lane 1)
extracts. RNA was analyzed as in Figure 2A. (B) Spliceosome assembly in U4/U6-depleted
extract (lanes 1–7) and mock-depleted extract (lanes 8–14). Spliceosomal complexes were
analyzed on a native gel at the indicated times. The positions of the H, A, and B complexes are
indicated on the right. (C) Spliceosome assembly in mock- vs. U4/U6-depleted extract.
Spliceosomal complexes were allowed to form under splicing conditions at 30°C for 20 min in
U4/U6-depleted nuclear extract (triangles) and mock-depleted extract (circles). Subsequently,
the complexes were separated on a 10%–30% glycerol gradient. The distribution of the
radioactivity across each gradient is shown. Peaks were assigned as A or B complex based on
their migration behavior according to Figure 1; the position of H complexes was verified
independently (data not shown).
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In both assembly pathway models, spliceosome forma-
tion involves a combination of pre-assembly and stepwise
recruitment of spliceosomal complexes/factors. Purified
yeast penta-snRNPs contained not only all five snRNPs
but also numerous non-snRNP-associated splicing factors
(Stevens et al. 2002). Nonetheless, they were not capable of
forming functional spliceosomal complexes without the
addition of soluble factors from yeast extract. Consistent
with this observation, mass spectrometry analyses revealed
that 15% of known splicing factors in yeast were not
present in purified penta-snRNP complexes (Stevens et al.
2002). Although some of these factors may have been
stripped off during purification, this observation indicates
that several functionally important factors—foremost step
II factors such as Slu7 and Prp18, and most DExD/H-box
RNA-dependent ATPases—are recruited stepwise to the
pre-mRNA, independent of the penta-snRNP. Indeed,
previous studies indicated that there is a dynamic exchange
of many spliceosomal proteins during the splicing cycle (for
review, see Will and Lu¨hrmann 2006). In the stepwise
assembly model, many spliceosomal proteins are preassem-
bled in the form of the snRNPs, and the U4/U6 and U5
snRNPs also interact with the pre-mRNA as a pre-formed
complex. Furthermore, some spliceosomal proteins also
appear to preassemble into multisubunit complexes prior
to engaging the pre-mRNA (e.g., proteins of the Prp19/
CDC5 complex). Thus, the stepwise assembly model also
entails the recruitment of preassembled spliceosomal sub-
complexes. Given the highly complex nature of the spli-
ceosome, it would be relatively inefficient to individually
recruit all of the >100 proteins comprising the splicing
machinery to each intron.
Preassembly of a penta-snRNP clearly would afford an
initial kinetic benefit, in that there would be a concomitant
recruitment of all snRNPs (plus many other factors) to the
pre-mRNA. This would alleviate assembly problems that
arise if the concentration of one or more spliceosomal
proteins is very low, and allow for a more rapid response to
regulatory signals. Nonetheless, a penta-snRNP complex
must still undergo multiple rearrangements after engaging
the pre-mRNA. That is, it is clear from numerous studies
that there is an ordered remodeling of not only RNA–RNA
interactions but also of those that are protein–protein or
protein–RNA in nature, over the course of splicing (Nilsen
1998; Will and Lu¨hrmann 2006). Maturation of the
spliceosome into a catalytically active entity thus requires
numerous remodeling events regardless of whether the vast
majority of spliceosomal components are recruited to the
pre-mRNA as a pre-formed complex or stepwise in the
form of multiple subcomplexes.
Stepwise recruitment of the U1 and U2 snRNPs followed
by the tri-snRNP, on the other hand, likely provides more
flexibility in terms of regulating the recognition and pairing
of the 59 and 39 splice sites. This may be particularly ad-
vantageous for higher eukaryotes in which alternative splicing
events—including those in which there is alternative pair-
ing of 59 and 39 splice sites—occur at a very high frequency.
That is, essentially no alternative splicing (with only minor
exceptions) is observed in both Schizosaccharomyces pombe
and S. cerevisiae, whereas 35%–65% of human genes are
alternatively spliced (Modrek and Lee 2002; Ast 2004).
Thus, it is conceivable that the holospliceosome pathway
of spliceosome formation may be less prevalent (or even
nonexistent) in higher eukaryotes.
The ability to purify functional spliceosome assembly
intermediates represents an important step for analyzing
both the structure and function of these complexes. For
example, future studies of the higher-order structure of the A
complex by electron microscopy should provide much needed
information about the 3D organization of the spliceosome
during its early stages of assembly. Furthermore, the com-
plexes isolated here can be used to reconstitute in vitro,
catalytically active spliceosomes from purified tri-snRNPs and
other spliceosomal proteins. These studies may potentially
lead to novel insights into the factor requirements for the
transition from the spliceosomal A complex to the B complex.
MATERIALS AND METHODS
In vitro transcription and nuclear extract preparation
A transcription template for the MINX pre-mRNA was generated
from pMINX plasmid (Zillmann et al. 1988) by PCR. MINX
FIGURE 4. Spliceosomal A complexes purified from U4/U6-
depleted nuclear extract are functional. (A) RNA composition of
spliceosomal complexes purified from U4/U6-depleted nuclear ex-
tract. RNA was analyzed as in Figure 2A and visualized by silver
staining (upper panel) or by autoradiography (lower panel). (B) Splic-
ing activity of A complexes purified from U4/U6-depleted extract.
Purified spliceosomal A complexes (lanes 1,2) or an equimolar mixture
of the purified A complex and naked, untagged MINX pre-mRNA
(lanes 3,4) were incubated in the presence of U2-depleted extract
for 3 h at 0°C (lane 1) or at 30°C (lanes 2,3), or for 3 h at 30°C in
U2-depleted extract complemented with 12S U2 snRNPs (lane 4).
RNA was analyzed as in Figure 2B.
In vitro assembly of functional A complexes
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pre-mRNA tagged with the J6f1 tobramycin RNA aptamer was
generated as described previously (Hartmuth et al. 2002). Uni-
formly [32P]-labeled, m7G(59)ppp(59)G-capped MINX and
MINX-To pre-mRNA were synthesized in vitro by T7 runoff
transcription as described previously (Hartmuth et al. 2002).
HeLa cell nuclear extract was prepared essentially according to
Dignam et al. (1983), except that initial cell lysis was performed
according to Bergamini et al. (2000) in MC Buffer (10 mM
HEPES-KOH at pH 7.6, 10 mM KOAc, 0.5 mM MgOAc, 5 mM
DTT, 13 Complete Protease Inhibitor [Roche]). U2-depleted
nuclear extract was prepared by affinity selection with a biotinylated
29-OMe RNA oligonucleotide complementary to nucleotides 1–20
of U2 snRNA (RNA-Tec) and streptavidin-agarose beads essen-
tially as described previously (Se´gault et al. 1995), except that the
oligonucleotide was used at a concentration of 14 mM and
dialysis was against buffer D (Dignam et al. 1983) without
glycerol (Do¨nmez et al. 2004). Similarly, an oligonucleotide
complementary to nucleotides 82–101 of U6 snRNA (RNA-Tec)
was used to deplete U4/U6 snRNP from nuclear extract as
previously described (Blencowe et al. 1989), except that no ATP
and creatine phosphate were added and that the oligonucleotide
was used at a concentration of 1.4 mM. Mock-depleted extracts
were prepared in an identical manner except that oligonucleo-
tide was omitted. RNA was recovered and analyzed on a 10%
polyacrylamide 8.3 M urea gel and visualized by staining with
ethidium bromide.
Purification of human spliceosomal A complexes
Rabbit polyclonal antibodies raised against a peptide (amino acids
444–458) of SF3a66 were affinity-purified using a SulfoLink
column (Pierce) containing the cognate peptide (Will et al.
2002). For immunoaffinity purification of spliceosomal com-
plexes, 220 mg of affinity-purified antibodies were covalently
coupled to 300 mL of protein A-Sepharose (PAS) beads with
dimethylpimelimidate. Solid phase splicing reactions and tobra-
mycin affinity selection of spliceosomal complexes were per-
formed as described previously (Hartmuth et al. 2002), except
that for a standard purification, 24 3 15-mL aliquots of matrix-
bound pre-mRNA were prepared, and each aliquot was incubated
for 45 min with 500 mL of a splicing reaction mixture. The latter
contained 35% HeLa cell nuclear extract or 40% U4/U6-depleted
nuclear extract. The tobramycin eluate (870 mL in total containing
280 nM pre-mRNA) was diluted with one volume of dilution
buffer (20 mM Tris-HCl at pH 8.1, 1 mM CaCl2, 3 mM MgCl2,
5.5 mM DTT, 6% glycerol) and incubated for 1.5 h at 4°C with
300 mL of anti-SF3a66 charged PAS beads preblocked with
0.5 mg/mL BSA and 50 mg/mL yeast tRNA. Beads were washed
three times with IP buffer (20 mM Tris-HCl at pH 8.1, 1 mM
CaCl2, 3 mMMgCl2, 5.5 mM DTT, 75 mM KCl, 3% glycerol), and
the bound material was specifically eluted by incubation for 2 h
with 320 mL of IP buffer containing 0.6 mg/mL of the cognate
peptide. The eluate was loaded onto a 4.1-mL, 10%–30% glycerol
gradient containing G75 buffer (20 mM HEPES-KOH at pH 7.9,
75 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT) and centrifuged in
a Sorvall TH660 rotor at 60,000 rpm for 1 h 47 min at 4°C.
Gradients were fractionated manually from top to bottom into
175-mL aliquots. RNA was recovered and analyzed on a 10%
polyacrylamide 8.3 M urea gel and visualized by silver staining
and autoradiography.
Isolation of 12S U2 snRNPs
A mixture of U1, U2, and U4/U6dU5 tri-snRNPs was isolated from
HeLa cell nuclear extract by anti-m3G immunoaffinity chroma-
tography (Bach et al. 1990). U2 snRNPs were subsequently
isolated by glycerol gradient centrifugation followed by ion
exchange chromatography (Bach et al. 1990) and dialyzed against
20 mM Tris-HCl (pH 7.9), 50 mM KCl, 1.5 mM MgCl2, and
2 mM DTT.
In vitro splicing assays
Standard splicing reactions contained 30% (v/v) U2 snRNP-
depleted nuclear extract or mock-depleted extract, 60 mM KCl,
3 mM MgCl2, 2 mM ATP, 20 mM creatine phosphate, and 1 nM
naked pre-mRNA (MINX pre-mRNA and/or MINX-To pre-
mRNA), purified A complex, or equimolar mixtures of naked
MINX pre-mRNA and purified A complex. Reactions were incu-
bated for 3 h at 30°C. For complementation of the U2-depleted
extract, purified 12S U2 snRNP was added to the splicing reaction
to a final concentration of 120 pmol/mL. The samples were
preincubated for 30 min on ice before addition of the pre-mRNA,
or an equimolar mixture of pre-mRNA and A complex. For
splicing analysis, RNA was recovered and separated on a 10%
polyacrylamide 8.3 M urea gel and detected by autoradiography.
For analysis of spliceosome assembly, MINX-To pre-mRNA was
incubated under splicing conditions as described above for 0–90
min, except that 40% extract was used. At defined time intervals,
0.5 mL of heparin (5 mg/mL) was added to 20-ml aliquots of the
splicing reaction. Splicing complexes were separated on a 2%
native agarose gel (Das and Reed 1999) and detected by auto-
radiography. Alternatively, 150 mL of a splicing reaction was
loaded without addition of heparin onto a 10%–30% glycerol
gradient containing G75 buffer and centrifuged as described
above. Gradients were fractionated manually from top to bottom
into 175-mL aliquots, and the distribution of ½32P-labeled pre-
mRNA across the gradient was determined by Cherenkov count-
ing in a scintillation counter.
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